<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1001" relname="joint">Proteases are associated with many signaling biological pathways ,</segment>
<segment id="3" parent="1004" relname="attribution">and it is has been proven</segment>
<segment id="4" parent="1004" relname="span">that the number of diseases like cancer , HIV , infectious diseases , and diabetes are treated</segment>
<segment id="5" parent="4" relname="means">by inhibiting proteases .</segment>
<segment id="6" parent="1006" relname="span">Pharmaceutical companies develop commercial drugs</segment>
<segment id="7" parent="6" relname="purpose">to inhibit aspartyl proteases , serine proteases , and cysteine proteases .</segment>
<segment id="8" parent="1008" relname="span">Among several protease inhibitors , serine protease inhibitors received significant interest in various applications</segment>
<segment id="9" parent="8" relname="elaboration">focused mainly in therapeutics .</segment>
<segment id="10" parent="1011" relname="span">Serine protease inhibitors</segment>
<segment id="11" parent="10" relname="elaboration">shown in Table 1 ,</segment>
<segment id="12" parent="1010" relname="same_unit">are used in treating diseases like immune-related disorders , inflammatory , respiratory , AIDS , neurodegenerative , and metabolic disorders .</segment>
<segment id="13" parent="1013" relname="preparation">Features like therapeutic potential , good binding affinity , low toxicity , and quickly cleavable by proteolytic enzymes ,</segment>
<segment id="14" parent="1014" relname="preparation">make cyclic peptides potential future therapeutics .</segment>
<segment id="15" parent="1017" relname="span">Most of the cyclic peptides</segment>
<segment id="16" parent="15" relname="elaboration">approved by the FDA</segment>
<segment id="17" parent="1017" relname="elaboration">( shown in Table 2 )</segment>
<segment id="18" parent="1015" relname="same_unit">are used in bacterial and fungal infections , oncology drugs , gastrointestinal disorders , and anemia .</segment>
<segment id="19" parent="1020" relname="span">Recently , cyclic peptides were proven to inhibit HIV-1 protease</segment>
<segment id="20" parent="19" relname="restatement">( aspartyl proteases )</segment>
<segment id="21" parent="1021" relname="span">and elastase ,</segment>
<segment id="22" parent="21" relname="elaboration">shedding light onto the use of cyclic peptides as protease inhibitors .</segment>
<segment id="23" parent="1023" relname="span">Phage display technology , Incretin-based cyclic peptide , cyclic peptides from mRNA display , and split-pool synthesis are some of the tools</segment>
<segment id="24" parent="1024" relname="span">used</segment>
<segment id="25" parent="24" relname="purpose">to develop cyclic peptide compounds .</segment>
<segment id="26" parent="1027" relname="span">Recently computer-aided drug design technologies like molecular docking simulations are applied</segment>
<segment id="27" parent="1028" relname="span">to identify , design rationally</segment>
<segment id="28" parent="27" relname="elaboration">( called as de novo developed ) ,</segment>
<segment id="29" parent="1026" relname="joint">and develop cyclic peptide ligand as leads to therapeutic drug targets of interest .</segment>
<segment id="30" parent="1030" relname="span">Till today , cyclic peptides as therapeutics</segment>
<segment id="31" parent="1031" relname="span">in regulating glucose metabolism</segment>
<segment id="32" parent="31" relname="means">by inhibiting proteases have not been reported for the treatment of diabetes mellitus .</segment>
<segment id="33" parent="1034" relname="span">In Mexico , approximately 11.5 million people live with diabetes mellitus</segment>
<segment id="34" parent="33" relname="elaboration">( DM ) ,</segment>
<segment id="35" parent="1033" relname="same_unit">which is the main leading cause of acquired blindness , non-traumatic lower-limb amputations , and chronic kidney failure diseases .</segment>
<segment id="36" parent="1038" relname="span">Human dipeptidyl peptidase-4</segment>
<segment id="37" parent="36" relname="elaboration">( DPP4 )</segment>
<segment id="38" parent="1037" relname="same_unit">is a serine protease ,</segment>
<segment id="39" parent="1039" relname="span">well known FDA-approved therapeutic drug target</segment>
<segment id="40" parent="1040" relname="joint">for regulating blood glucose metabolism</segment>
<segment id="41" parent="1040" relname="joint">and treating diabetes mellitus .</segment>
<segment id="42" parent="1043" relname="span">Sitagliptin , Vildagliptin , Anagliptin , Saxagliptin , and Alogliptin are the main clinically used chemicals for human dipeptidyl peptidase-4</segment>
<segment id="43" parent="42" relname="restatement">( DPP4 )</segment>
<segment id="44" parent="1044" relname="span">inhibition</segment>
<segment id="45" parent="44" relname="circumstance">despite their side effects as pancreatitis , nausea , and anemia .</segment>
<segment id="46" parent="1047" relname="attribution">It is well known</segment>
<segment id="47" parent="1048" relname="span">that incretin hormones glucagon-like peptide 1</segment>
<segment id="48" parent="47" relname="restatement">( GLP-1 )</segment>
<segment id="49" parent="1050" relname="span">and glucose-dependent insulinotropic polypeptide</segment>
<segment id="50" parent="49" relname="elaboration">( GIP )</segment>
<segment id="51" parent="1049" relname="same_unit">are responsible for insulin release and glucose regulation .</segment>
<segment id="52" parent="1052" relname="span">These hormones are inactivated by a serine protease human dipeptidyl peptidase-4</segment>
<segment id="53" parent="52" relname="elaboration">( DPP4 ) .</segment>
<segment id="54" parent="1029" relname="joint">Since natural cyclic peptides are proven to inhibit various proteases ,</segment>
<segment id="55" parent="1055" relname="preparation">and to consider the beneficial aspects of cyclic peptides in comparison to small chemicals , like less toxicity , no accumulation in organs , and rapid degradation of peptides ,</segment>
<segment id="56" parent="1057" relname="attribution">we hypothesized</segment>
<segment id="57" parent="1057" relname="span">that cyclic peptides from natural sources could be an alternative source of therapeutics</segment>
<segment id="58" parent="57" relname="purpose">to inhibit serine protease DPP4 for treatment of diabetes mellitus .</segment>
<segment id="59" parent="1055" relname="joint">Among various naturally occurring cyclic peptides ,</segment>
<segment id="60" parent="1062" relname="span">oxytocin</segment>
<segment id="61" parent="60" relname="elaboration">( natural cyclic peptide )</segment>
<segment id="62" parent="1061" relname="same_unit">was chosen in this study</segment>
<segment id="63" parent="1063" relname="span">to prove our hypothesis</segment>
<segment id="64" parent="63" relname="elaboration">that , cyclic peptides possess serine protease inhibition activity ,</segment>
<segment id="65" parent="1064" relname="span">and specifically inhibit DPP4 .</segment>
<segment id="66" parent="1065" relname="joint">To demonstrate our hypothesis ,</segment>
<segment id="67" parent="1067" relname="span">activity atlas and field-based models of DPP4 inhibitors from natural origin were utilized</segment>
<segment id="68" parent="67" relname="purpose">to elucidate molecular insights of oxytocin peptide into DPP4 inhibition .</segment>
<segment id="69" parent="1069" relname="span">In addition , molecular docking simulations were used</segment>
<segment id="70" parent="1070" relname="span">to understand the binding poses and interacting residues</segment>
<segment id="71" parent="70" relname="elaboration">responsible for inhibitory activity .</segment>
<segment id="72" parent="1072" relname="span">Also , the stability of water molecules at the binding site of oxytocin was studied</segment>
<segment id="73" parent="1074" relname="span">using 3D reference interaction site model</segment>
<segment id="74" parent="73" relname="restatement">( 3D-RISM )</segment>
<segment id="75" parent="1074" relname="purpose">to gain deep insights into the binding of the cyclic peptide at DPP4 druggable region .</segment>
<segment id="76" parent="1075" relname="span">Finally , fluorescence assay was used</segment>
<segment id="77" parent="76" relname="purpose">to demonstrate the potential role of oxytocin as a DPP4 inhibitor experimentally .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1003" type="span" parent="1001" relname="joint"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1006" type="span" parent="1001" relname="joint"/>
<group id="1008" type="span" parent="1001" relname="joint"/>
<group id="1010" type="multinuc" parent="1001" relname="joint"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="span" parent="1001" relname="joint"/>
<group id="1013" type="span" parent="1012" relname="span"/>
<group id="1014" type="multinuc" parent="1013" relname="span"/>
<group id="1015" type="multinuc" parent="1014" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="same_unit"/>
<group id="1017" type="span" parent="1016" relname="span"/>
<group id="1019" type="multinuc" parent="1014" relname="joint"/>
<group id="1020" type="span" parent="1019" relname="same_unit"/>
<group id="1021" type="span" parent="1019" relname="same_unit"/>
<group id="1023" type="span" parent="1014" relname="joint"/>
<group id="1024" type="span" parent="23" relname="elaboration"/>
<group id="1025" type="multinuc" parent="1014" relname="joint"/>
<group id="1026" type="multinuc" parent="1025" relname="sequence"/>
<group id="1027" type="span" parent="1026" relname="joint"/>
<group id="1028" type="span" parent="26" relname="purpose"/>
<group id="1029" type="multinuc" parent="1025" relname="sequence"/>
<group id="1030" type="span" parent="1029" relname="joint"/>
<group id="1031" type="span" parent="30" relname="elaboration"/>
<group id="1033" type="multinuc" parent="1029" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="same_unit"/>
<group id="1036" type="multinuc" parent="1029" relname="joint"/>
<group id="1037" type="multinuc" parent="1036" relname="same_unit"/>
<group id="1038" type="span" parent="1037" relname="same_unit"/>
<group id="1039" type="span" parent="1036" relname="same_unit"/>
<group id="1040" type="multinuc" parent="39" relname="purpose"/>
<group id="1042" type="multinuc" parent="1029" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="same_unit"/>
<group id="1044" type="span" parent="1042" relname="same_unit"/>
<group id="1046" type="span" parent="1029" relname="joint"/>
<group id="1047" type="multinuc" parent="1046" relname="span"/>
<group id="1048" type="span" parent="1047" relname="same_unit"/>
<group id="1049" type="multinuc" parent="1047" relname="same_unit"/>
<group id="1050" type="span" parent="1049" relname="same_unit"/>
<group id="1052" type="span" parent="1029" relname="joint"/>
<group id="1054" type="span" parent="1029" relname="joint"/>
<group id="1055" type="multinuc" parent="1054" relname="span"/>
<group id="1056" type="span" parent="1055" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="span"/>
<group id="1060" type="span" parent="1055" relname="joint"/>
<group id="1061" type="multinuc" parent="1060" relname="span"/>
<group id="1062" type="span" parent="1061" relname="same_unit"/>
<group id="1063" type="span" parent="1061" relname="purpose"/>
<group id="1064" type="span" parent="1055" relname="joint"/>
<group id="1065" type="multinuc" parent="65" relname="purpose"/>
<group id="1066" type="multinuc" parent="1065" relname="joint"/>
<group id="1067" type="span" parent="1066" relname="joint"/>
<group id="1068" type="multinuc" parent="1066" relname="joint"/>
<group id="1069" type="span" parent="1068" relname="joint"/>
<group id="1070" type="span" parent="69" relname="purpose"/>
<group id="1071" type="multinuc" parent="1068" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="sequence"/>
<group id="1073" type="span" parent="72" relname="means"/>
<group id="1074" type="span" parent="1073" relname="span"/>
<group id="1075" type="span" parent="1071" relname="sequence"/>
	</body>
</rst>
